DNA, Drugs and Doctors: How Genes Affect Your Response to Drugs

3:15 – 4:15 pm

Grand Ballroom 8B
Convention Level
(Entrance through corridor between Grand Ballrooms 7 & 8)

Adverse drug reactions (ADRs) are considered the fourth most common cause of death among Americans. Imagine a future where the risk of ADRs can be managed or even eliminated. That future is here in the field of pharmacogenomics, which is the study of how one’s genetic makeup will affect an individual’s response to drugs – a combination of pharmacology and genomics. The FDA now includes pharmacogenomics information on the labels of over 200 drugs. For certain drug classes, gene variants among individuals may help determine the best selection and dose of a drug. As a result, pharmacogenomics may hold the key to reducing risk associated with drug therapy. However, does this new field offer anything to workers’ compensation? In this session, a risk manager and clinical pharmacist will discuss the risks of drug treatment especially as it relates to opioids. This will be followed by a discussion between two physicians as to whether the medical community is ready to utilize this new information, and whether pharmacogenomics will have a broad impact on the treatment and recovery of injured workers.

Phil Walls, RPh
Chief Clinical Officer
myMatrixx, an Express Scripts Company
Tampa, FL

Will Franken
Corporate Risk Manager
Seaboard Corporation
Merriam, KS

Dan Hunt, DO
Corporate Medical Director
Accident Fund Holdings, Inc
Lansing, MI

Steven Stanos, DO
Medical Director
Swedish Health System
Seattle, WA


View All Sessions